











































Protective Role of Mytilus edulis Hydrolysate in
Lipopolysaccharide-Galactosamine Acute Liver Injury
Citation for published version:
Starikova, E, Mammedova, J, Ozhiganova, A, Lebedeva, A, Malashicheva, A, Semenova, D, Khokhlova, E,
Mameli, E, Caporali, A, Wills, J & Sokolov, A 2021, 'Protective Role of Mytilus edulis Hydrolysate in
Lipopolysaccharide-Galactosamine Acute Liver Injury', Frontiers in pharmacology, vol. 12.
https://doi.org/10.3389/fphar.2021.667572
Digital Object Identifier (DOI):
10.3389/fphar.2021.667572
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
  
 
Protective role of Mytilus edulis
hydrolysate in Lipopolysaccharide-
Galactosamine acute liver injury
 
Eleonora Starikova1, 2*, Jennet T. Mammedova1, Arina I. Ozhiganova1, Alexandra M.
Lebedeva1, Anna B. Malashicheva3, 4, Daria Sergeevna S. Semenova3, 4, Eleonora Mameli5,
Andrea Caporali5, Jimi С. Wills6, Alexey V. Sokolov1
 
1Institute of Experimental Medicine, Russia, 2Pavlov First Saint Petersburg State Medical University,
Russia, 3Almazov National Medical Research Centre, Russia, 4Institute of Cytology, Russia, 5Centre for
Cardiovascular Science, University of Edinburgh, United Kingdom, 6Cancer Research Centre, University
of Edinburgh, United Kingdom
 Submitted to Journal:








 13 Feb 2021
 Revised on:
 14 Apr 2021





 Conflict of interest statement
 The authors declare that the research was conducted in the absence of any commercial or financial
relationships that could be construed as a potential conflict of interest
  
 Author contribution statement
 
Eleonora Starikova and Alexey Sokolov were responsible for the conception and design of the study; Eleonora Starikova wrote the
main manuscript text; Jennet Mammedova , Arina Ozhiganova, Alexandra Lebedeva, Anna Malashicheva , Daria Semenova and
Eleonora Mameli conducted the experiments and statistical analysis; Andrea Caporali, Jimi Wills conducted the experiments and
statistical analysis, critically reviewed and revised the paper. All authors contributed to the study and manuscript preparation and
approved the submitted version.    Figure 4. The effect of N2-01 on NO production by the human umbilical endothelial cells. Note.
Here and further, statistical assessment of differences was performed using one-way analysis of variance (ANOVA), and pairwise
comparison of the mean values was performed using the Tukey HSD test. The data is presented as mean ± standard error of the









Acute liver injury in its terminal phase trigger systemic inflammatory response syndrome with multiple organ failure. An
uncontrolled inflammatory reaction is difficult to treat and contributes to high mortality. Therefore, to solve this problem a
search for new therapeutic approaches remains urgent. This study aimed to explore the protective effects of M. edulis
hydrolysate (N2-01) against Lipopolysaccharide-D-Galactosamine (LPS/D-GalN)-induced murine acute liver injure and the underlying
mechanisms. N2-01 analysis, using Liquid Chromatography Mass Spectrometry (LCMS) metabolomic and proteomic platforms,
confirmed composition, molecular-weight distribution, and high reproducibility between M. edulis hydrolysate manufactured
batches. N2-01 efficiently protected mice against LPS/D‑GalN‑induced acute liver injury. The most prominent result (100% survival
rate) was obtained by the constant subcutaneous administration of small doses of the drug. N2-01 decreased Vascular Cell Adhesion
Molecule-1 (VCAM-1) expression from 4.648±0.445 to 1.503±0.091 MFI and Interleukin-6 (IL-6) production in activated Human
Umbilical Vein Endothelial Cells (HUVECs) from 7.473±0.666 to 2.980±0.130 ng/ml in vitro. The drug increased Nitric Oxide (NO)
production by HUVECs from 27.203±2.890 to 69.200±4.716 MFI but significantly decreased inducible Nitric Oxide Synthase (iNOS)
expression from 24.030±2.776 to 15.300±1.290 MFI and NO production by murine peritoneal lavage cells from 6.777±0.373 µM to
2.175±0.279 µM. The capability of the preparation to enhance the endothelium barrier function and to reduce vascular
permeability was confirmed in Electrical Cell-substrate Impedance Sensor (ECIS) test in vitro and Miles assay in vivo. These results
suggest N2-01 as a promising agent for treating a wide range of conditions associated with uncontrolled inflammation and
endothelial dysfunction.
  
 Contribution to the field
A systemic inflammatory reaction is a serious complication for a number of diseases, and is difficult to treat. In particular, the
latest statistics on coronavirus infection show that. The development of new drugs aimed at suppressing the inflammatory
response with minimal side effects is an urgent medical task. This study demonstrates that permanent subcutaneous
administration of M. edulis hydrolysate with 100% efficiency increases the survival rate of mice in the model of acute liver injury,
the last stage of which is accompanied by the development of a systemic inflammatory reaction. It was found that the main points
of application of the drug could be suppression of endothelial cell activation, a decrease in vascular permeability, as well as
selective inhibition of iNOS activity. The study shows that M. edulis hydrolysate can be considered as a promising drug for the
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Abstract 25 
Acute liver injury in its terminal phase trigger systemic inflammatory response syndrome with multiple 26 
organ failure. An uncontrolled inflammatory reaction is difficult to treat and contributes to high 27 
mortality. Therefore, to solve this problem a search for new therapeutic approaches remains urgent. 28 
This study aimed to explore the protective effects of M. edulis hydrolysate (N2-01) against 29 
Lipopolysaccharide-D-Galactosamine (LPS/D-GalN)-induced murine acute liver injure and the 30 
underlying mechanisms. N2-01 analysis, using Liquid Chromatography Mass Spectrometry (LCMS) 31 
metabolomic and proteomic platforms, confirmed composition, molecular-weight distribution, and 32 
high reproducibility between M. edulis hydrolysate manufactured batches. N2-01 efficiently protected 33 
mice against LPS/D‑GalN‑induced acute liver injury. The most prominent result (100% survival rate) 34 
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was obtained by the constant subcutaneous administration of small doses of the drug. N2-01 decreased 35 
Vascular Cell Adhesion Molecule-1 (VCAM-1) expression from 4.648±0.445 to 1.503±0.091 MFI and 36 
Interleukin-6 (IL-6) production in activated Human Umbilical Vein Endothelial Cells (HUVECs) from 37 
7.473±0.666 to 2.980±0.130 ng/ml in vitro. The drug increased Nitric Oxide (NO) production by 38 
HUVECs from 27.203±2.890 to 69.200±4.716 MFI but significantly decreased inducible Nitric Oxide 39 
Synthase (iNOS) expression from 24.030±2.776 to 15.300±1.290 MFI and NO production by murine 40 
peritoneal lavage cells from 6.777±0.373 µM to 2.175±0.279 µM. The capability of the preparation to 41 
enhance the endothelium barrier function and to reduce vascular permeability was confirmed in 42 
Electrical Cell-substrate Impedance Sensor (ECIS) test in vitro and Miles assay in vivo. These results 43 
suggest N2-01 as a promising agent for treating a wide range of conditions associated with uncontrolled 44 
inflammation and endothelial dysfunction.  45 
1 Introduction 46 
Septic shock is a massive uncontrolled inflammatory reaction accompanied by excessive 47 
production of inflammatory cytokines and violation of vascular homeostasis, manifested as 48 
hypotension and peripheral vasodilation. The subsequent collapse of blood circulation, refractory to 49 
intravascular volume replacement and vasopressors, leads to hypoperfusion of organs followed by 50 
multiple organ failure (Shapiro et al., 2006). Neither the significant progress made in the study of the 51 
sepsis pathophysiology nor the use of various strategies for the treatment of septic shock has allowed 52 
any significant improvement in survival in this pathology (Berg and Gerlach 2018). The frequency of 53 
immune system disorders with pro-and anti-inflammatory cytokine production impairment and 54 
systemic inflammatory response syndrome (SIRS) development remains significantly high, accounting 55 
for 40% of deaths in intensive care units (Punyadeera et al., 2010; Vincent et al., 2019). Therefore, the 56 
development of new therapeutic drugs that can suppress an excessive inflammatory reaction without 57 
compromising the immune system's main protective mechanisms remains relevant. Marine fauna is a 58 
resource providing great opportunities to develop new biopharmaceuticals (Ahmad et al., 2019). 59 
Mytilus edulis (M. edulis) is a typical marine bivalve that inhabits coastal rocks. M. edulis derivatives 60 
were shown to contain biologically active substances that can effectively regulate inflammation 61 
(Cheonget et al., 2017; Kim et al., 2016; Lindqvist et al., 2018), blood clotting (Jung and Kim, 2009; 62 
Qiao et al., 2018; Feng et al., 2017) and oxidative stress (Wang et al., 2013; Grienke et al., 2014). M. 63 
edulis broth sauce is traditionally used in China to enhance immune reactions and treat liver and kidney 64 
dysfunctions (Li and Ding, 2006). But the usage of M. edulis derivatives against the SIRS has not yet 65 
been investigated and needs to be studied. Therefore, the present study aims to look into the possible 66 
protective role of M. edulis hydrolysate (N2-01) in murine model Lipopolysaccharide-D-67 
Galactosamine (LPS/D-GalN) acute liver injury in vivo, and the underlying mechanisms in vitro. 68 
2 Materials and methods 69 
2.1 Preparation and characterization of M. edulis hydrolysate (N2-01) 70 
M. edulis for N2-01 preparation were harvested on the west coast of Scotland and the Shetland 71 
Islands; alive mussels were adequately processed, the mussels' meat composition of each lot was 72 
analyzed, and stored at -70°C. N2-01 was produced from the standardized composition of mussel 73 
meat through a patented (EP2911678B1) hydrolysis process. The sustainability of the lab-scale pre-74 
GMP production was confirmed by the IGMM (Institute of Genetics & Molecular Medicine) Mass 75 
Spectrometry laboratory (University of Edinburgh). N2-01 (in its undiluted form) was diluted 40:1 in 76 
5:3:2 methanol:acetonitrile:water and 10uL were injected onto a ZIC-pHILIC 4.6mm x 150mm 77 
Sequant column (Merck, UK) on an Ultimate 3000 series HPLC (Thermo Fisher Scientific, USA) 78 
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with A gradient from 90%-5% B in 20 minutes, where A was 20mM ammonium carbonate and B 79 
was acetonitrile. Data were acquired on Q Exactive (Thermo Fisher Scientific, USA) with HESI in 80 
positive (75.5 to 1132.5) and negative (77.5 to 1132.5) mode at 70k resolution, with ddMS2 at 17.5k.  81 
Quantitative comparisons and primary identification were done in Compound Discoverer 2.1 82 
(Thermo Scientific).  Further identification was done in PEAKS 7.5 (Bioinformatics Solutions Inc.)  83 
2.2 Animals  84 
Eight‐week‐old male C57BL/6 mice, white mongrel female and CBA/BALB male (F1) mice (all 85 
received from "Rappolovo" nursery, St. Petersburg, RF) were housed at 24 ± 1°C, a 12 h light-dark 86 
cycle and relative humidity of about 40–80% conditions. Animal experiments were carried out at the 87 
Institute of Experimental Medicine, St-Petersburg, according to Animal Welfare Assurance №2/19 88 
from 25.03.2019.   89 
2.3 Murine model of LPS/D-GalN acute liver injury 90 
C57BL/6 mice were used in the experiments. The study was carried out as described in [Galanos et 91 
al., 1979]. 92 
Each mouse was intraperitoneally administered 500 μl (25 ml/kg) mixture, containing 200 ng (0.01 93 
mg/kg) of LPS from E. coli, strain O26: B6 (No. L-2762, Sigma-Aldrich, USA) and 5 mg (250 94 
mg/kg) of D-GalN (Vekton, RF). Saline was used for sham treatment. The experiment was carried 95 
out using 4 groups of animals. The test group received 0.1 (5 ml/kg or 20 ml/kg per day), 0.2 (10 96 
ml/kg or 40 ml/kg per day) and 0.4 (20 ml/kg or 80 ml/kg per day) ml N2-01 4 times per day 97 
intraperitoneally at 8:00 AM, 12:00 PM, 4:00 PM and 8:00 PM (36, 36 and 12 mice were included in 98 
each group respectively). The control group (36 mice included) received sterile saline at the same 99 
time points. A single dose of 5 mg (250 mg/kg) of antibodies against the macrophages migration 100 
inhibiting factor (MIF) in 0.4 ml (20 ml/kg) of the physiological solution was used as the active 101 
control (6 mice included). 102 
An additional experiment with 8 animals in each group was performed with the subcutaneous 103 
implantation of Alzet osmotic pumps (Models 1003D, Nominal Pumping Rate 1.0 µl/hr (0.05 ml/kg 104 
per hour or 1.2 ml/kg per day). Nominal Duration 3 days. Nominal Reservoir 100 µl, DURECT 105 
Corporation, Cupertino, CA) containing 0.1 ml (5 ml/kg) of N2-01(test group) or physiological 106 
solution (control group). Osmotic Pumps implantation was performed as described in (Krogman et 107 
al., 2016). The mortality rate was recorded every 24 hrs and Kaplan-Meier’s plots were created. 108 
2.4 Miles assay: vascular permeability 109 
The level of vascular permeability was assessed in white mongrel female mice using Evans blue dye 110 
as previously described (Brash et al, 2018). 22 animals in each group studied. To determine 111 
extravascular protein leakage in vivo, Evans blue dye (0.2 ml (10 ml/kg) of 0.2% solution in PBS) 112 
(DIA-M, RF), which can bind quantitatively to serum albumin, was injected intravenously through 113 
the tail vein. After 10 min, mice were anaesthetized using isoflurane (AbbVie Inc., UK) inhalation. 114 
Prior to vascular hyperpermeability stimulation, 100 µl (5 ml/kg) of N2-01 was injected in the 115 
withers subcutaneously. Animals of the control group were administered with saline instead of N2-01 116 
in the same manner. Then 20 µl (1 ml/kg) of compound 48-80 known to induce vascular leakage 117 
(Ashina et al., 2015), in concentration 3µg/ml was administered intradermally (Sigma-Aldrich, USA) 118 
in the right flank. Simultaneously, N2-01 (test group) or PBS (control group) were injected 119 
subcutaneously into the withers. The animals were euthanized by cervical dislocation in 20 min after 120 
the Evans blue injection. The skin regions comprising the leakage of Evans blue dye at the site of 121 
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permeability-inducing agent injection were excised using punch. The skin samples were stored at - 122 
20°C until further use. Evans blue was extracted from the skin by incubation in 0.2 ml of formamide 123 
(Sigma-Aldrich, USA) for 24 hrs, centrifuged 5.000 g for 10 min. 0.1 ml of the supernatant of each 124 
sample were collected into flat-bottom 96-well plates (Sarstedt, Germany). The concentration of 125 
Evans blue was quantified by measuring the absorbance at 620 nm using a Microplate Reader 126 
(BioRad, USA). The results were expressed as optical density.  127 
2.5 Isolation of human umbilical vein endothelial cells 128 
Endothelial cells from human umbilical veins were isolated as previously described (Baudin et al., 129 
2007). Umbilical cords were obtained from the perinatal centre of the Almazov National Medical 130 
Research Centre. Ethics committee of the Almazov National Medical Research center approved the 131 
research protocol for the study “Investigation of cellular and molecular bases of aortic pathologies 132 
using tissue obtained from the leftovers after surgical interventions”. Ethical permit number 133 
12.26/2014. The form of uniformed content for the patients enrolled in the study is approved by 134 
Ethics committee of the Almazov National Medical Research center. Primary cultures of human 135 
umbilical vein endothelial cells (HUVEC) were grown in Endothelial Cell Basal Medium-2 (ECBM-136 
2) (Promocell, Germany) with Supplement Mix (Promocell, Germany), 10% fetal calf serum (FCS) 137 
(HyClone, USA), 4 mM glutamine, 50 µ/ml penicillin, 50 µ/ml streptomycin in tissue culture flasks 138 
(Sarstedt, Germany) which had been pre-coated with 0,2% gelatin (Sigma, USA) at 37°C in a 139 
humidified atmosphere with 5% CO2. Subculturing was performed twice a week. The monolayer 140 
disintegration was caused by cells incubation in Trypsin-EDTA solution (Sigma, USA). Cells from 141 
3-5 passage were used in experiments. 142 
2.6 The assessment of NO production by HUVEC  143 
To analyze NO production, HUVECs were plated into 12-well flat-bottom plates (Sarstedt, Germany) 144 
and cultured to form a confluent monolayer. After that, N2-01 was added, and cells were incubated 145 
37°C in a humidified atmosphere of 5% CO2. LPS from E. coli O111:B4 (Sigma-Aldrich, USA) in 146 
concentration 100µg/ml was added for the last 24 hrs of incubation. At the end of the incubation 147 
period, the DAF-FM DA dye (Invitrogen, USA) was added at a concentration of 1µM in each well. 148 
After 1 h incubation, the dye was washed off, the monolayers were disintegrated, and the cells were 149 
fixed with a 4% formaldehyde solution (Sigma, USA). Here and further, the samples for flow 150 
cytometry were analyzed using a Navios ™ flow cytometer (Beckman Coulter, USA). The results 151 
were expressed as Mean Fluorescence Intensity (MFI). 152 
2.7 Real-time Quantitative PCR 153 
RNA from cultured cells was isolated using ExtractRNA (Eurogene, RF). Total RNA (0,5 μg) was 154 
reverse transcribed with MMLV RT kit (Eurogen, RF). Real-time Quantitative PCR was performed 155 
with 1 μL cDNA and SYBRGreen PCRMastermix (Eurogen, RF) in the Light Cycler system using 156 
specific forward and reverse primers for target genes. Corresponding gene expression level was 157 
normalized to GAPDH from the same samples. Changes in target genes expression levels were 158 
calculated as fold differences using the comparative ΔΔCT method. Primer sequences were  159 
human ICAM-1:  160 
F - 5’ - CGGCCAGCTTATACACAAGAAC - 3’,  161 
R - 5’ - TGGCACATTGGAGTCTGCTG - 3’ ; 162 
human VCAM-1:  163 
F 5’ -CAGTAAGGCAGGCTGTAAAAGA - 3’,  164 
R 5’ - TGGAGCTGGTAGACCCTCG - 3’ ; 165 
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human IL-6:  166 
F 5’ - GCTCTGTGTGAAGGTGCAGTT - 3’ 167 
R 5’ - GTGGTCCACTCTCAATCACTCT - 3’. 168 
2.8 Analysis of endothelial cells adhesion molecules expressions 169 
To evaluate the expression of VCAM-1 (CD106) and ICAM-1 (CD54) adhesion molecules, 170 
HUVECs were seeded into 24-well flat-bottom plates (Sarstedt, Germany) at a concentration of 150 171 
000 cells per ml. Then, the N2-01 in different dilutions was added for 72 hrs. 24 hrs before the end of 172 
incubation, 100µg/ml LPS from E. coli O111:B4 (Sigma-Aldrich, USA) was added into the test 173 
wells, and the same volume of vehicle was added into the control wells. The expression of surface 174 
molecules was evaluated by flow cytometry using phycoerythrin (PE) labelled anti-CD106 (Beckman 175 
Coulter, USA, cat. No. PN A66085), anti-CD54 monoclonal antibodies (Beckman Coulter, USA, cat. 176 
№ PN IM1239U) and isotype control antibody mouse IgG1-PE (Becman Coulter, USA, Cat. No PN 177 
IM0670). Single-cell suspensions staining was performed following the manufacturer's 178 
recommendation. To exclude dead cells from the analysis, the cells were stained with 1 mg/ml DNA-179 
binding dye DAPI (Invitrogen, USA). 180 
2.9 Analysis of IL-6 production by HUVEC 181 
HUVECs were seeded into 24-well flat-bottom plates (Sarstedt, Germany) at a concentration of 150 182 
000 cells per ml and N2-01 in different dilutions with or without 50 U/ml TNFα 183 
("Refnolin","Ferment", Sanitas, Lithuania, specific activity - 1 U-0.06 ng) was added. After 24 hrs, 184 
culture medium samples were collected and stored at -20°C. The assessment of IL-6 concentration in 185 
the samples was performed using a human IL-6 ELISA kits (Cytokine, RF), following the 186 
manufacturer's instructions. 187 
2.10 Analysis of nitrite and nitrate concentrations in mouse peritoneal lavage cell supernatants 188 
The experiments were carried out with CBA/BALB (F1) mice. Experiments were performed as 189 
described previously (Migliorini et al., 1991). The cells were received by the wash of the peritoneal 190 
cavity with 5 ml Hanks solution supplemented with 2% FCS (HyClone, USA). After a single 191 
washing by centrifugation 5 min 200 g, cells were seeded into 96-well flat-bottom plates (Eppendorf, 192 
Germany) at the density of 300, 000 per well in 100 µl of RPMI 1640 medium (Biolot, RF) 193 
supplemented with 10% FCS (HyClone, USA), 2 mM glutamine (Biolot, RF), 50 µg/ml gentamicin 194 
(Biolot, RF) and incubated for 24 hrs in a humidified atmosphere 37°C, 5% CO2. After the culture 195 
medium replacement, the N2-01 was added in each well in different concentrations. To stimulate NO 196 
production, LPS from E. coli 055:B5 (Sigma-Aldrich, Germany) was added at 1 µg/ml. After 24 hrs 197 
of incubation at 37°C and 5% CO2, the cells were centrifuged for 5 min at 200g. Next, 70 µl of the 198 
supernatants were transferred into 96-well flat-bottom plates (Eppendorf, Germany), and 70 µl of 199 
Griess reagent in each well was added. The spectrometric analysis was performed at a wavelength of 200 
540 nm (Microplate reader, Model 680, Bio-Rad). The concentration of nitrites and nitrates in 201 
experimental samples was determined statistically, in accordance with a linear approximation using 202 
the least-squares method, based on a calibration curve constructed using a solution of sodium nitrite 203 
(NaNO2) of the known concentration. Cellular precipitations obtained were used for subsequent 204 
determination of the level of iNOS expression. Experiments were performed in triplicates with 6 205 
animals in each repeat. 206 
2.11 Analysis of iNOS expression in peritoneal lavage cells 207 
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Peritoneal lavage cells were transferred into tubes for flow cytometry (Sarstedt, Germany). 208 
Fixation/permeabilization was performed by incubation in 500 µl in ice-cold 80% methanol (Vecton, 209 
RF) for 10 min at -20°C. After a single wash by centrifugation at 200 g for 7 min, the cell suspension 210 
was stained with APC/Cy7 labelled anti-CD45 monoclonal antibodies (Biolegend, USA cat. 211 
No.103116) or isotype control antibody rat IgG2b APC/Cy7 (Biolegend, USA, Cat. No 147718), and 212 
FITC labelled monoclonal antibodies against iNOS (BD Transduction Laboratories, USA Cat. No. 213 
610330), following manufacturer's recommendations. CD45 – positive cells were included in the 214 
analysis. 215 
2.12 Analysis of endothelial monolayer barrier function using ECIS 216 
Endothelial barrier function was continuously recorded using the 8W10E+ electrode chamber arrays 217 
and ECIS Z-Theta system (both Applied Biophysics, USA) with associated software, as described in 218 
(Tiruppathi et al., 1992). Human brain endothelial cells (purchased from CellBiologics, USA) were 219 
cultured in Complete Human Endothelial Cell Medium (CellBiologics, USA), plated in fibronectin-220 
coated (Merck, UK; 10 µg/ml) 8W10E+ array, and grown to confluency to form an endothelial 221 
monolayer. The cells were pre-treated with N2-01 for 48 hrs and then stimulated with LPS from E. 222 
coli O111:B4 (Merks, UK; 1mg/ml) for 24 hrs. The capacity of N2-01 to restore barrier function in 223 
response to LPS has been monitored and recorded for 24 hrs.   224 
2.13 Statistical analysis 225 
Kolmogorov-Smirnov test was used to confirm the normality of the distribution. In the studies of the 226 
production of NO and IL-6, the expression of iNOS and adhesion molecules, the ICAM-1, VCAM-1 227 
and IL-6 transcripts expression, as well as the barrier function of the endothelial monolayer, the 228 
differences between test and control groups were estimated using one-way analysis of variance 229 
(ANOVA). Group-wise comparisons were performed with post hoc Tukey HSD test. Survival of 230 
mice in of D-GalN/LPS-induced liver injury was compared using the Log-rank test for trend. 231 
Differences in vascular permeability in the control and experimental groups of animals in Miles assay 232 
were estimated using Student’s t-test. Statistical analysis was performed using STATISTICA 7.0, 233 
Graph Pad Prism and Microsoft Office Excel 2010 software and a value of P < 0.05 was considered 234 
statistically significant. 235 
3 Results 236 
3.1 Composition and Reproducibility of N2-01 237 
LCMS `omic analysis of N2-01 revealed an overview of its molecular composition and molecular-238 
weight distribution and confirmed high reproducibility between manufactured batches. HILIC LC-239 
MS/MS, performed in positive and negative modes, revealed a complex mixture of components, 240 
mostly peptides. Protein assay and standard proteomics indicated no measurable proteins remain after 241 
hydrolysis (data not shown).  Compound discoverer identified 9473 unique molecular weights from 242 
the ion maps, suggesting molecular formulae for 4253 of these and giving unequivocal matches to 243 
498 named compounds.  PEAKS matched 1822 peptides from the Uniprot bivalve sequences, though 244 
many more had spectra characteristic of peptides. Compound Discoverer gave a name to 46% of the 245 
total ion intensity in 3 analyzed batches, with greater than 13% of the total intensity being attributed 246 
to amino acids but less than 1.5% to dipeptides (Figure 1).  Greater than 5% of the total intensity was 247 
attributed to fatty acids and more than 20% attributed to other named metabolites. Amino acids, 248 
dipeptides and short peptides were also measured by PEAKS.  Short peptides were in the mass range 249 
344-698 with a median of 389.  PEAKS identified slightly more of the amino acid and peptide 250 
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associated intensity than Compound Discoverer, and the values from PEAKS are used in Figure 1B.  251 
That is PEAKS assigned 14%, 17% and 1.2% of the total ion intensity to amino acids, dipeptides and 252 
short peptide, respectively, indicating the extent of hydrolysis.  48% of the total ion intensity remains 253 
unassigned (Supplementary Tables S1, S2).  Mass spectrometry confirmed the composition one 254 
might expect from such a hydrolysate. 255 
Preparation of N2-01 was reproducible between batches.  Focusing on the 5000 features most stable 256 
between repeat injections, from the most reproducible part of the HPLC gradient, repeat injections 257 
still accounted for 47.2% of the variability observed in the principal component analysis. 258 
Simultaneously, three batches (batches 4, 5 and 6) compared separated in component 2 with just 259 
19.7%.  The explained variance in PLS-DA was 22.9% in separating the batches, with component 2 260 
having a variance 39.2%.  Therefore, it is clear that batch production is very reproducible, to the 261 
extent that the vast majority of variation comes from sample-processing and measurement and not 262 
batch-to-batch variation, even when the selection of data favours repeat-injection stability.  The 263 
reproducibility of batch preparation is illustrated in Figure 2A.  The data are normally distributed 264 
when log-transformed, with a mean correlation coefficient of 0.92.  Figure 2B shows that the CVs 265 
(RSDs) between batches are not very different from repeat injections, and the median CV (17%) is 266 
the same for both dimensions (Supplementary Table S3). Figure 2C shows comparison of batches, 267 
technical repeats, and contrasts M. edulis hydrolysates with those of other species. Note that while 268 
the different starting materials cluster apart, it is the technical repeats that cluster rather than batches 269 
of N2-01, further indicating that batch differences are minimal. LCMS data used in this paper are 270 
available at ftp://massive.ucsd.edu/MSV000087104/ 271 
 272 
3.2 N2-01 increase animals survival rate in the murine model LPS/GalN acute liver injury 273 
It was shown that 0.1 ml (5 ml/kg) N2-01 administered 4 times per day doubled the survival rate of 274 
the animals (Figure 3A). In comparison, the mortality in the control group was 50%, the mortality in 275 
the N2-01 group animals made up only 25%. It should be noted that the mortality rate in the test N2-276 
01 group was registered in the morning (8:00 AM) before the administration of the next drug dose, 277 
rather than in the evening of the same day (the drug injection period). Therefore, it was suggested 278 
that either the N2-01 dose or the evenness of its administration during the day should be increased to 279 
enhance the effect. So, higher doses of the N2-01 – 0.2 (10 ml/kg) and 0.4 ml (20 ml/kg) were used 280 
in the next experiment. The increase in the drug dosage did not improve survival, and the mortality 281 
rate in the test groups (0.2 and 0.4 ml of N2-01) was nearly the same at all the time intervals (Figure 282 
3 A, B, C). At the next stage, the animals have implanted Alzet osmotic pumps that uniformly 283 
released 1.0 µl/h (0.05 ml/kg per hour or 1.2 ml/kg per day) of the drug in 3 days’ time after the 284 
implantation. 100% of the mice with Alzet pumps with the N2-01 implanted survived until the 4th 285 
observation day (Figure 3D), while in the control group, 6 of the 8 mice died by the 4th day (i. e. the 286 
mortality rate was 75%).  287 
3.3 N2-01 anti-inflammatory action in vitro 288 
It was shown that liver damage and systemic inflammatory reaction with the development of 289 
endothelial dysfunction play an important role in LPS/GalN-induced liver injury pathogenesis 290 
(Zhang et al., 2014). Liver damage is associated, in particular, with increased production of nitric 291 
oxide (NO) (Tsai et al.,2018), the product of NOS activity. At least three isoforms of this enzyme, 292 
which differ in function, cell expression, and regulation mechanisms were described (Sass et al., 293 
2001). Of these, eNOS=NOS3 (endothelial NOS) is constitutively expressed by vascular endothelial 294 
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cells and produces NO at low concentration to maintain vascular homeostasis (Sass et al., 2001). 295 
iNOS=NOS2 – isoform is induced in immune cells under the influence of pro-inflammatory factors 296 
such as TNF-α, IFN-γ, LPS, etc. (Sass et al., 2001). iNOS overexpression has been described in many 297 
pathologies associated with the development of acute and chronic inflammation, including septic 298 
shock and hepatitis (Sass et al., 2001). To evaluate the action of the N2-01 on the activity of eNOS 299 
and iNOS isoforms of the enzyme, in further experiments, the effect of the drug on spontaneous and 300 
LPS-induced NO production by HUVECs and mouse peritoneal lavage cells were studied. It was 301 
shown that LPS did not affect the production of NO by endothelial cells (Figure 4). At the same time, 302 
N2-01 in all dilutions significantly increased the production of NO.  303 
On the contrary, N2-01 significantly suppressed spontaneous and LPS-induced NO production by 304 
murine peritoneal lavage cells in the dilution range from 1/3 to 1/12 (Figure 5B). Besides, the drug 305 
reduced spontaneous and induced by LPS iNOS expression (Figure 5A). The results suggested that 306 
N2-01 can enhance eNOS and inhibit iNOS activity. 307 
The development of inflammatory reaction in LPS induced liver injury is accompanied by increased 308 
inflammatory cytokine productions and vascular endothelial adhesiveness (van Oosten et al., 1995). 309 
To test the potential anti-inflammatory properties of N2-01, the drug effect on the inducible adhesion 310 
molecules VCAM-1 and ICAM-1 expression on HUVECs was studied. In addition, the influence of 311 
N2-01 on IL-6 productions by endothelial cells was assessed. It was found that incubation of cells 312 
with the N2-01 in dilution 1/3 resulted in a significant decrease in the spontaneous level of VCAM-1 313 
expression (Figure 6B). All dilutions of N2-01 showed significant reductions in the level of VCAM-1 314 
expression induced by LPS. The drug also decreased the spontaneous and LPS induced level of 315 
ICAM-1 expression, but in this case, its effect was not statistically significant (Figure 6A). 316 
Inflammatory cytokines IL-6 and TNF-α are involved in LPS/D-GalN-induced hepatic damage (Li et 317 
al., 2018). As an essential source and target of cytokines, endothelium plays a crucial role in 318 
inflammation and amplifies tissue damage. This investigation showed that N2-01 significantly 319 
decreased IL-6 productions by resting and TNFα-activated endothelial cells (Figure 7). Further, the 320 
assessment of ICAM-1, VCAM-1 and IL-6 gene expression levels by quantitative PCR was 321 
performed. The qPCR results showed downregulation of ICAM-1, VCAM-1 and IL-6 mRNA 322 
expression under the influence of N2-01, but the effect was not statistically significant (Figure 8 A, 323 
B, C). 324 
3.4 N2-01 restore endothelial barrier integrity 325 
Pro-inflammatory mediators via autocrine and paracrine mechanism contribute to endothelial 326 
dysfunction, endothelial barrier integrity disruption, and extravascular fluid accumulation. Clinical 327 
observations showed that patients with sepsis usually develop progressive subcutaneous and body 328 
cavity oedema, which indicates a systemic increase in vascular permeability. Those can impair organ 329 
function by increasing the distance required for oxygen diffusion and disrupting microvascular 330 
perfusion due to increased interstitial pressure (Lee and Slutsky, 2010). Exposure to LPS induces 331 
morphological changes in endothelial cells, such as cell contraction, disruption of endothelial 332 
junctions, and loss of focal contacts with the underlying extracellular matrix, thus allowing the 333 
opening of endothelial monolayer (Bannerman and Goldblum, 1999). The response of the endothelial 334 
monolayer barrier to LPS can be assessed in real-time in a fully standardized manner by continuously 335 
recording changes in resistance changes using ECIS (Tiruppathi et al., 1992).  For this assay, human 336 
brain endothelial cells were used because of the high level of tight junctions in comparison to 337 
endothelial cells from peripheric organs (Helms et al., 2016). To functionally test the effect of N2-01 338 
on monolayer permeability after LPS stimulation, human primary brain microvascular endothelial 339 
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cells grown to form a tight monolayer in 8W10E+ array slides were pre-treated with N2-01 at 340 
different dilutions, and changes in resistance of the endothelial monolayers were continuously 341 
recorded for 48 hours (Figure 9A). As shown in Figure 6B, the N2-01 treatment increased the 342 
endothelial monolayer resistance. The formed endothelial monolayer was then treated with LPS 343 
(1mg/ml), and changes in resistance were recorded for 24 hours (Figure 9A). N2-01 activity on 344 
resistance became significantly evident 4 h after the beginning of treatment with LPS and persisted 345 
for more than 12 hours. As indicated by the resistance values, the N2-01 treatment reduced the LPS-346 
mediated permeability in the endothelial monolayers (Figure 9D). 347 
Further, we evaluated the effect of N2-01 on extravascular protein leakage in Miles Assay in vivo 348 
(Ashina et al., 2015). The control group mice showed increased extravasation of Evans blue dye than 349 
the mice that were injected with N2-01 (Figure 10A). The control group mice showed increased 350 
extravasation of Evans blue dye in the tissue than the mice injected with N2-01 (Figure 10A). 351 
Quantitative analysis of Evans blue dye extracted from the mice's skin showed that N2-01 352 
significantly (compared to the group receiving PBS) reduced vascular permeability induced by 353 
substance 48/80 (Figure 10B). 354 
4 Discussion 355 
In this study, evidence was obtained that N2-01, a preparation of M. edulis hydrolysate, significantly 356 
increases the survival rate of mice in the model of LPS/GalN acute liver injury (Figure 3). It was 357 
found that the effectiveness of the drug depends on the route of administration. While the mortality 358 
rate of mice with dosed administration of the drug was 25% (Figure 3 A, B, C), constant 359 
administration of small doses (1.0 µl/hr or 0.05 ml/kg per hour) of the drug using Mini-Osmotic 360 
Pump (Figure 3D) improved mice survival up to 100%. Based on these data, it can be assumed that 361 
due to the high rate of N2-01 catabolism, the drug's constant administration is required to achieve the 362 
maximum positive effect. 363 
Increased NO production is an essential pathogenetic factor that contributes to aggravating the 364 
development of acute liver injury (Guler et al., 2004). Depending on the concentration, NO can have 365 
opposite biological effects, and the metabolite production is regulated by activation of different NOS 366 
isoforms (Wink and Mitchell, 1998). LPS induces iNOS expression in leukocytes and leads to the 367 
production NO in high concentrations (>1 µM), which causes cell damage and contributes to the 368 
amplification of an inflammatory response (Sass et al., 2001). D-GalN increases animals' sensitivity 369 
to LPS and LPS-induced production of inflammatory mediators significantly (Tang et al., 2019). 370 
Another eNOS isoform of the enzyme is constitutively expressed in endothelial cells and produces 371 
low concentrations of NO (<1 µM), essential for maintaining vascular homeostasis (Cinelli et al., 372 
2020). Our data show that the protective effect of the N2-01 in murine model LPS/D-GalN‐ acute 373 
liver injury may be related to its ability to restore the balance of iNOS and eNOS activity, returning 374 
NO production to physiological values (Figure 4 and 5) 375 
Experimental and clinical data indicate that LPS/D-GalN induced toxic shock is accompanied by the 376 
overproduction of reactive oxygen species and peroxynitrite, developing severe oxidative stress with 377 
increased endothelium adhesiveness and damage (Korish and Arafa, 2011). In this study, it was also 378 
found that N2-01 decreased VCAM-1 expression (Figure 6) and IL-6 production (Figure 7) in 379 
endothelial cells, and decreased endothelium permeability (Figure 9 and 10). These results confirm 380 
earlier obtained data that the >5 kDa peptide fraction of M. edulis hydrolysate suppressed LPS-381 
induced production of NO, prostaglandin E2 (PGE2) and pro-inflammatory cytokines TNF-α, 382 
interleukin-6, and interleukin-1b in RAW 264 macrophage cells (Kim et al, 2016; Park et al.,2014). 383 
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The action of >5 kDa M. edulis hydrolysate peptide fraction was associated with inhibition of NF-κB, 384 
MAPK signalling pathways, expression of iNOS and cyclooxygenase-2 (Kim et al, 2016; Park et 385 
al.,2014).  386 
We hypothesis that N2-01 drug's action is based on its ability to control the renin-angiotensin system 387 
(RAS). The primary function of RAS is traditionally considered to be the regulation of blood 388 
pressure. Recently, however, there has been evidence that RAS is also involved in the regulation of 389 
the inflammatory process. Antihypertensive classes of drugs, angiotensin-converting enzyme (ACE) 390 
and bradykinin inhibitors, are currently widely used to reduce inflammation in several diseases, such 391 
as atherosclerosis, arthritis, steatohepatitis, colitis, pancreatitis and nephritis (Ranjbar et al., 2019). It 392 
was found that a shift in the balance towards ACE2 within RAS leads to a decrease in iNOS activity, 393 
expression of adhesion molecules, production of pro-inflammatory cytokines, and restoration of the 394 
eNOS function (Ranjbar et al., 2019). Studies on rats with spontaneous hypertension showed that the 395 
hydrolysate obtained from blue mussel meat has ACE inhibitory activity (Je et al., 2005; Neves et al. 396 
2015).  397 
The ability of N2-01 to protect against LPS/D‑GalN‑induced acute liver injury could be attributed to 398 
the inhibition of inflammatory cytokines and normalization of NO production leading to the 399 
inhibition of endothelial cells adhesion molecule expression and vascular permeability. Whether the 400 
effect of N2-01 is realized by correcting the imbalance of RAS homeostasis remains to be confirmed. 401 
The anti-inflammatory effects of N2-01 established in our study make it a promising drug for use in 402 
different conditions associated with endothelial dysfunction and inflammation, such as systemic 403 
inflammatory response syndrome, oncological, neurodegenerative processes and pain syndromes. 404 
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Figure 1. N2-01composition by mass-spectrometry. (A) Percentage of total ion intensity 561 
explained by Compound Discoverer and PEAKS for production batches 4, 5 and 6 combined. (В) 562 
Chromatogram of batch 6, negative mode top, positive mode bottom. 563 
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Figure 2.  Panel A shows scatter plot of feature intensities of batches 2-6 vs batch 1, 564 
illustrating the reproducibility between batches.  Panel B compares the CVs (RSDs) of identified 565 
compounds across repeat injections and across batches. Panel C is a heatmap generated in R version 566 
4.0.0 (2020-04-24) of scaled log intensity reported by Compound Discoverer for those compounds 567 
identified (mostly small molecules, not peptides).  Compounds with multiple features were summed 568 
(Supplementary Methods).  Technical repeats, a and c are shown for N2-01 batches 4, 5 and 6, 569 
alongside 7 and 8 which are octopus and squid respectively.  570 
Figure 3. Effects of N2-01 treatment on LPS/GalN‐induced lethality. (A) 0.1 ml N2-01 (4 time 571 
per day), (B) 0.2 ml N2-01 (4 time per day), (C) 0.4 ml N2-01 (4 time per day), (D) 1.0 µl/h N2-01 was 572 
infused with Alzet osmotic pumps. Group survival was compared using a Logrank test Logrank test for 573 
trend. 574 
Figure 4. The effect of N2-01 on NO production by the human umbilical endothelial cells. Note. 575 
Statistical assessment of differences was performed using ANOVA (p<0.001), and pairwise 576 
comparison of the mean values was performed using the Tukey HSD test. Data are expressed as 577 
mean± standard error of the mean (SEM) of at least four individual experiments (n = 4). The 578 
differences are significant: ** p<0.01 vs PBS; ##  p<0.01 vs LPS. 579 
Figure 5. The effect of N2-01 on iNOS (A) expression level and NO (B) production by mouse 580 
peritoneal lavage cells. Statistical assessment of differences was performed using ANOVA, and 581 
pairwise comparison of the mean values was performed using the Tukey HSD test. Data are expressed 582 
as mean±SEM of at least three individual experiments (n = 3). The differences are significant: a) 583 
ANOVA p<0.05; # - p<0.05 vs LPS; b) ANOVA p<0.001; * - p<0.05, *** - p<0.001 vs control; ## - 584 
p<0.01 vs LPS. 585 
Figure 6. The effect of N2-01 on the ICAM-1 (A) and VCAM-1 (B) adhesion molecules 586 
expression on the human umbilical endothelial cells. Statistical assessment of differences was 587 
performed using ANOVA (p<0.001), and pairwise comparison of the mean values was performed using 588 
the Tukey HSD test. Data are expressed as mean±SEM of at least four individual experiments (n = 4). 589 
The differences are significant: ** - p<0.01 vs control; ## - p<0.01 vs LPS. 590 
Figure 7. The effect of N2-01 on the IL-6 productions by human umbilical endothelial cells. 591 
Statistical assessment of differences was performed using ANOVA (p<0.001), and pairwise 592 
comparison of the mean values was performed using the Tukey HSD test. Data are expressed as 593 
mean±SEM of nine individual experiments (n = 9).The differences are significant: ** - p<0.01 vs 594 
control, *** - p<0.001 vs control; ### - p<0.001 vs TNFα. 595 
Figure 8. The effect of N2-01 on the VCAM-1 (A), ICAM-1 (B) adhesion molecules and IL-6 596 
transcripts in human umbilical endothelial cells (C). Statistical assessment of differences was 597 
performed using ANOVA (p<0.001), and pairwise comparison of the mean values was performed using 598 
the Tukey HSD test. Data are expressed as mean±SEM  of three individual experiments (n = 3).The 599 
differences are significant: ** - p<0.01 vs control. 600 
Figure 9. Effect of N2-01 on barrier function. Endothelial cells were pre-treated with N2-01 601 
for 48h and then stimulated with LPS (1mg/ml) for 24 hours. The capacity of N2-01 to restore barrier 602 
function in response to LPS has been monitored and recorded for 24 hours.  (A) Line graph showing 603 
the measurement of resistance of endothelial monolayer after N2-01 treatment at indicated doses. (B) 604 
Bar graphs show the data of average resistance measurements continuously recorded for and at 48 605 
hours. (C) Line graph showing the measurement of resistance of endothelial monolayer after LPS 606 
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15 
treatment for 24 hours. (D) Bar graphs show the data of average resistance measurements 607 
continuously recorded for and at 24 hours. Data are presented as mean± SD of four individual 608 
experiments(n=4). For (B) and (D): ** p<0.01 vs PBS; # p<0.05 vs LPS. 609 
Figure 10. The effect of N2-01 on vascular permeability A, B. Note. Statistical assessment of 610 
differences was performed using Student`s t-test. The data are presented as mean ± SEM (n=22).  611 
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